Glycyrrhizic Acid Attenuates Sepsis-Induced Acute Kidney Injury by Inhibiting NF- B Signaling Pathway

Evidence-based Complementary and Alternative Medicine

Volumn 2016, Issue , 2016, Pages

  Zhao, Hongyu ^a   Zhao, Min ^a   Wang, Yu ^a   Li, Fengchun ^a   Zhang, Zhigang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOOXYGENASE 2; GLYCYRRHIZIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UREA;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CECAL LIGATION AND PUNCTURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ENZYME INHIBITION; HISTOPATHOLOGY; KIDNEY PARENCHYMA; LIGATION; MALE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCTURE; RAT; SEPSIS; SHAM PROCEDURE; SIGNAL TRANSDUCTION; SURVIVAL RATE; UREA NITROGEN BLOOD LEVEL;

EID: 84958212539     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2016/8219287     Document Type: Article

References (40)

1. D. E. Fry, "Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues," American Surgeon, vol.78, no.1, pp. 1-8, 2012.
2. P. S. Tipler, J. Pamplin, V. Mysliwiec, D. Anderson, and C. A. Mount, "Use of a protocolized approach to the management of sepsis can improve time to first dose of antibiotics," Journal of Critical Care, vol. 28, no. 2, pp. 148-151, 2013.
3. K. Grozdanovski, Z. Milenkovic, I. Demiri, and K. Spasovska, "Prediction of outcome from community-acquired severe sepsis and septic shock in tertiary-care university hospital in a developing country," Critical Care Research and Practice, vol. 2012, Article ID 182324, 6 pages, 2012.
4. H. L. Cronshaw, R. Daniels, A. Bleetman, E. Joynes, and M. Sheils, "Impact of the surviving sepsis campaign on the recognition and management of severe sepsis in the emergency department: are we failing?" Emergency Medicine Journal, vol. 28, no. 8, pp. 670-675, 2011.
5. R. S. Hotchkiss, G. Monneret, and D. Payen, "Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach," The Lancet Infectious Diseases, vol.13, no. 3, pp. 260-268, 2013.
6. S. M. Bagshaw, C. George, and R. Bellomo, "Early acute kidney injury and sepsis: a multicentre evaluation," Critical Care, vol. 12, no. 2, article R47, 2008.
7. S. Rajapakse, C. Rodrigo, A. Rajapakse, D. Kirthinanda, and S. Wijeratne, "Renal replacement therapy in sepsis-induced acute renal failure," Saudi Journal of Kidney Diseases and Transplantation, vol. 20, no. 4, pp. 553-559, 2009.
8. L. Wu, N. Gokden, and P.R. Mayeux, "Evidence for the role of reactive nitrogen species in polymicrobial sepsis-induced renal peritubular capillary dysfunction and tubular injury," Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1807-1815, 2007.
9. N. Abe, T. Ebina, and N. Ishida, "Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice," Microbiology and Immunology, vol. 26, no. 6, pp. 535-539, 1982.
10. M. Baba and S. Shigeta, "Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro," Antiviral Research, vol. 7, no. 2, pp. 99-107, 1987.
11. L. J. Ming and A. C. Y. Yin, "Therapeutic effects of glycyrrhizic acid," Natural Product Communications, vol. 8, no. 3, pp. 415- 418, 2013.
12. O. A. Pliasunova, T. V. Il'ina, I. Kiseleva et al., "The anti-HIV activity of glycyrrhizic acid penta-O-nicotinate," Vestnik RossiѤskoѤ Akademii Meditsinskikh Nauk, no. 11, pp. 42-46, 2004.
13. Z. Y. Wang and D. W. Nixon, "Licorice and cancer," Nutrition and Cancer, vol. 39, no. 1, pp. 1-11, 2001.
14. Y. Arase, K. Ikeda, N. Murashima et al., "The long term efficacy of glycyrrhizin in chronic hepatitis C patients," Cancer, vol. 79, no. 8, pp. 1494-1500, 1997.
15. T. G. J. van Rossum, A. G. Vulto, W. C. J. Hop, and S. W. Schalm, "Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C," American Journal of Gastroenterology, vol. 96, no. 8, pp. 2432-2437, 2001.
16. K.-L. Li, J.-G. Zhang, H.-M. Wang, and J. Chen, "The effects of glycyrrhizin-18alpha on the expression of NF-kappaB in the renal interstitium of rats with obstructive nephropathy," Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, vol. 20, no. 1, pp. 31-33, 2004.
17. S. Hou, F. Zheng, Y. Li, L. Gao, and J. Zhang, "The protective effect of glycyrrhizic acid on renal tubular epithelial cell injury induced by high glucose," International Journal of Molecular Sciences, vol. 15, no. 9, pp. 15026-15043, 2014.
18. X. Bi, G. Zhu, Z. Han et al., "Protective effect of glycyrrhizin on nephrotic syndrome induced by adriamycin in rats," Clinical and Investigative Medicine, vol. 32, no. 3, pp. E229-E238, 2009.
19. K. Doi, A. Leelahavanichkul, P. S. T. Yuen, and R. A. Star, "Animal models of sepsis and sepsis-induced kidney injury," The Journal of Clinical Investigation, vol. 119, no. 10, pp. 2868-2878, 2009.
20. T. Miyaji, X. Hu, P. S. T. Yuen et al., "Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice," Kidney International, vol. 64, no. 5, pp. 1620-1631, 2003.
21. R. Hilton, "Defining acute renal failure," CMAJ, vol. 183, no. 10, pp. 1167-1169, 2011.
22. W. J. Hubbard, M. Choudhry, M. G. Schwacha et al., "Cecal ligation and puncture," Shock, vol. 24, supplement 1, pp. 52-57, 2005.
23. G. M. Chertow, E. Burdick, M. Honour, J. V. Bonventre, and D. W. Bates, "Acute kidney injury, mortality, length of stay, and costs in hospitalized patients," Journal of the American Society of Nephrology, vol. 16, no. 11, pp. 3365-3370, 2005.
24. A. Grenz, J.-H. Kim, J. D. Bauerle, E. Tak, H. K. Eltzschig, and E. T. Clambey, "Adora2b adenosine receptor signaling protects during acute kidney injury via inhibition of neutrophil-dependent TNF-α release," Journal of Immunology, vol. 189, no. 9, pp. 4566-4573, 2012.
25. J.-W. Lee, W.-J. Nam, M.-J. Han et al., "Role of IL-1alpha in cisplatin-induced acute renal failure in mice," Korean Journal of Internal Medicine, vol. 26, no. 2, pp. 187-194, 2011.
26. S. J. Lee, E. Borsting, A.-E. Declèves, P. Singh, and R. Cunard, "Podocytes express IL-6 and lipocalin 2/neutrophil gelatinase-associated lipocalin in lipopolysaccharide-induced acute glomerular injury," Nephron-Experimental Nephrology, vol. 121, no. 3-4, pp. e86-e96, 2012.
27. S. Heemskerk, R. Masereeuw, F. G. M. Russel, and P. Pickkers, "Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury," Nature Reviews Nephrology, vol. 5, no. 11, pp. 629-640,2009.
28. B. Hauser, H. Bracht, M. Matejovic, P. Radermacher, and B. Venkatesh, "Nitric oxide synthase inhibition in sepsis? Lessons learned from large-animal studies," Anesthesia and Analgesia, vol. 101, no. 2, pp. 488-498, 2005.
29. M. M. Tiwari, R. W. Brock, J. K. Megyesi, G. P. Kaushal, and P. R. Mayeux, "Disruption of renal peritubular blood flow in lipopolysaccharide-induced renal failure: role of nitric oxide and caspases," The American Journal of Physiology - Renal Physiology, vol. 289, no. 6, pp. F1324-F1332, 2005.
30. S. Heemskerk, P. Pickkers, M. P. W. J. M. Bouw et al., "Upregulation of renal inducible nitric oxide synthase during human endotoxemia and sepsis is associated with proximal tubule injury," Clinical Journal of the American Society of Nephrology, vol. 1, no. 4, pp. 853-862, 2006.
31. D. A. Kniss, "Cyclooxygenases in reproductive medicine and biology," Journal of the Society for Gynecologic Investigation, vol. 6, no. 6, pp. 285-292, 1999.
32. C. F. Nathan, "Secretory products of macrophages," Journal of Clinical Investigation, vol.79, no. 2, pp. 319-326, 1987.
33. P. N. Cunningham, H. M. Dyanov, P. Park, J. Wang, K. A. Newell, and R. J. Quigg, "Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney," Journal of Immunology, vol. 168, no. 11, pp. 5817-5823, 2002.
34. S. K. Jo, D. R. Cha, W. Y. Cho et al., "Inflammatory cytokines and lipopolysaccharide induce fas-mediated apoptosis in renal tubular cells," Nephron, vol. 91, no. 3, pp. 406-415, 2002.
35. J. M. Adams and S. Cory, "Life-or-death decisions by the Bcl-2 protein family," Trends in Biochemical Sciences, vol. 26, no. 1, pp. 61-66, 2001.
36. M. Adamzik, S. Schäfer, U. H. Frey et al., "The NFKB1 promoter polymorphism (-94ins/delATTG) alters nuclear translocation of NF-κB1 in monocytes after lipopolysaccharide stimulation and is associated with increased mortality in sepsis," Anesthesiology, vol. 118, no. 1, pp. 123-133, 2013.
37. M. Xu, F. Cao, L. Liu et al., "Tanshinone IIA-induced attenuation of lung injury in endotoxemic mice is associated with reduction of hypoxia-inducible factor 1α expression," American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 5, pp.1028-1035, 2011.
38. S. Aosasa, S. Ono, H. Mochizuki, H. Tsujimoto, C. Ueno, and A. Matsumoto, "Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes," Shock, vol. 15, no. 2, pp. 101-105, 2001.
39. Y.-J. Surh, K.-S. Chun, H.-H. Cha et al., "Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation," Mutation Research, vol. 480-481, pp. 243-268, 2001.
40. 2 production by suppressing cyclooxygenase-2 upregulation and Akt-dependent activation of nuclear factor-κB in human lung epithelial cells," Journal of Pharmacological Sciences, vol. 114, no. 2, pp. 225-229, 2010.